The PDf file transcript of the entire call is here. I apparently inadvertently omitted one questioner, in my summary-style (quick) live-blog, on Thursday morning — taken in real-time — so I’ll set that fuller exchange below, thus:
. . . .[Transcript]
▲ Marc Goodman (UBS) — What’s the similarity between the stroke and the ACS patients, if it’s not bleeding, I guess, is the question.
▲ Dr. Peter Kim (Merck: President, Merck Research Laboratories) — Well, again, in the communication to the investigators, the study chairs did not state the reason that the DSMB made the recommendation.
▲ Marc Goodman (UBS) — Well, what would you say would be the similarity between those two patient populations and why they’re similar?
▲ Dr. Peter Kim (Merck: President, Merck Research Laboratories) — I’m really not in a position to speculate at this point, Marc. . . .
We’ll keep you posted — but this makes a strong case that the near-term “full-value” price of Merck’s stock is around. . . . $35 — until the thick fog of the J&J arbitration uncertainty lifts, at least.